G-Protein coupled receptor signalling in pluripotent stem cell-derived cardiovascular cells: implications for disease modelling

Nazanin F. Dolatshad1, Nicola Hellen1, Richard Jabbour1, Sian E. Harding1*, Gabor Foldes1

1NHLI, Imperial College London, United Kingdom

Submitted to Journal:
Frontiers in Cell and Developmental Biology

Specialty Section:
Stem Cell Treatments

ISSN:
2296-634X

Article type:
Review Article

Received on:
24 May 2015

Accepted on:
09 Nov 2015

Provisional PDF published on:
09 Nov 2015

Frontiers website link:
www.frontiersin.org

Citation:

Copyright statement:
© 2015 Dolatshad, Hellen, Jabbour, Harding and Foldes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
G-Protein coupled receptor signalling in pluripotent stem cell-derived cardiovascular cells: implications for disease modelling

N.F. Dolatshad*1, N. Hellen*1, R. Jabbour*1, S.E. Harding1, G. Foldes1,2

1 National Heart and Lung Institute, Imperial College London, London, United Kingdom
2 Heart and Vascular Center, Semmelweis University, Budapest, Hungary

Running title: GPCRs and pluripotent stem cells

* These authors contributed equally to this work and are listed alphabetically.

Number of words: 7731
Number of figures: 2

Correspondence:
Sian E Harding
National Heart and Lung Institute
Imperial College London
Imperial Centre for Experimental and Translational Medicine
Hammersmith Campus
Du Cane Road
London W12 0NN
United Kingdom
Email: sian.harding@imperial.ac.uk
Abstract
Human pluripotent stem cell derivatives show promise as an in vitro platform to study a range of human cardiovascular diseases. A better understanding of the biology of stem cells and their cardiovascular derivatives will help to understand the strengths and limitations of this new model system. G-protein coupled receptors (GPCRs) are key regulators of stem cell maintenance and differentiation and have an important role in cardiovascular cell signalling. In this review, we will therefore describe the state of knowledge concerning the regulatory role of GPCRs in both the generation and function of pluripotent stem cell derived-cardiomyocytes, -endothelial and -vascular smooth muscle cells. We will consider how far the in vitro disease models recapitulate authentic GPCR signalling and provide a useful basis for discovery of disease mechanisms or design of therapeutic strategies.

Key words: G-protein coupled receptor, pluripotent, stems cells, cardiovascular, disease modelling
1. General description of GPCRs

GPCRs are heterotrimeric proteins consisting of α, β, and γ subunits that can bind to both guanosine triphosphate (GTP) and guanosine diphosphate (GDP) nucleotides. G-protein-coupled receptors (GPCRs) are seven-transmembrane domain receptors (7TM receptors), which function through their interaction with G-proteins inside the cell. They can amplify extracellular signals to produce robust, varied, and cell-specific responses including chemotaxis, neurotransmission, cell growth, differentiation and communication. GPCRs can bind a diverse range of ligands from large proteins to photons (Kristiansen, 2004) and also have a wide range of ligand-binding mechanisms (Gether et al., 2002). There are more than 800 GPCRs in the human genome, making it the largest receptor superfamily. GPCRs are divided into five distinct families using bioinformatic analysis: Glutamate, Rhodopsin, Adhesion, Frizzled and Secretin (GRAFS classification system) (Fredriksson et al., 2003; Fredriksson et al., 2001; Gloriam et al., 2007). An up to date list of all human GPCRs as agreed by the International Union of Pharmacology subcommittee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) can be found at http://www.guidetopharmacology.org/.

GPCR signalling is activated via the receptor G-protein α-subunit, which can be divided into four major classes comprising of Gs, Gi, Gq, and G12/13, with each class consisting of multiple subtypes. To date 16 α subunits have been identified, with a total of 23 different isoforms. In addition, 5 β subunits and 12 γ subunits have also been identified in the human genome. There are multiple combinations of various isoforms that exist for each of the three G-protein subunits and the signalling pathways activated by them (Figure 1) (Li et al., 2002; Tuteja, 2009).

While all GPCRs share common features such as their 7TM structure, interaction with the intracellular heterotrimeric G proteins and internalisation, it is important to note that Frizzled (FZD) receptors which consist of 10 members and classed separately in this superfamily do not all follow the same signalling mechanism as the other members and will be further discussed later. (Foord et al., 2005; Gloriam et al., 2007).

Approximately 50–60% of all existing medicines are believed to target GPCRs (Fredriksson et al., 2003) and play a fundamental role in cardiovascular regeneration. By identifying the physiological role of GPCRs and their respective downstream signalling pathways, our understanding of many cardiovascular conditions has increased and new treatments have been developed. Indeed, two of the most prognostically important medications in treating heart failure target GPCRs and their pathways: 1) beta-adrenergic (β-AR) pathway blockers and 2) angiotensin converting enzyme (ACE) inhibitors/Angiotensin II receptor type 1 blockers (Salazar et al., 2007; Kober et al., 1995; Hunt et al., 2009; McMurray et al., 2012).

Among an estimated 200 cardiac GPCRs (Salazar et al., 2007), drugs targeting adrenergic and angiotensin pathways alone account for the majority of prescriptions in cardiovascular diseases (Tang et al., 2004). In this review we aim to give an overview of the role of GPCRs in human pluripotent stem cells and their cardiovascular derivatives.

2. GPCRs in human pluripotent stem cells (hPSC)

GPCRs exert a multitude of effects in pluripotent stem cells. A wide range of GPCRs are expressed in human embryonic stem cells (hESCs) (Layden et al., 2010; Nakamura et al., 2009). Evidence exists for their roles in stem cell maintenance (Pebay et al., 2005; Inniss et al., 2006; Wong et al., 2007), pluripotency/self-renewal (Kobayashi et al., 2010; Layden et al., 2010; Faherty et al., 2007; Callihan et al., 2011), migration (Miller et al., 2008; McGrath...
et al., 1999) and survival (Jiang et al., 2007; Wong et al., 2007) (summarised in table 1). Less research however has been performed with human induced pluripotent stem cells (hiPSC).

2.1. Maintenance and survival

GPCRs have an important role in stem cell maintenance. Lysophospholipid signalling, mediated by sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA), control a wide range of cellular processes including stem cell maintenance via their respective GPCRs; S1P1, 5 and LPA1-5. Signalling is mediated through phospholipase C (PLC), extracellular signal-regulated kinases 1/2 (ERK1/2), adenylate cyclase (AC), Ca2+ mobilisation and activation of small GTPases. hESCs express both S1P1-3 and LPA1-5 (Pebay et al.; 2005, Dottori et al., 2008). S1P in combination with platelet derived growth factor (PDGF) is responsible for the maintenance of hESC in an undifferentiated state via G_i- and ERK-dependent mechanisms leading to the activation of pro-survival pathways, apoptosis inhibition and increased proliferation (Pebay et al., 2005; Inniss et al., 2006; Wong et al., 2007). From studies performed in murine ESC (mESC) expression of both CB1 and CB2 cannabinoid receptors have been detected and demonstrated to have a role in ESC survival (Jiang et al., 2007). Furthermore, the expression of the endocannabinoid receptor, 2-AG, may also contribute to ESC survival. The stromal cell derived factor 1 (SDF1 or CXCL12)/CXCR4 pathway which is widely known for its role in cell migration has also been found to enhance survival of mESC (Guo et al., 2005). To date, the role of these pathways has not been thoroughly investigated in hESCs/hiPSCs.

2.2. Self-renewal/pluripotency

Expression and activation of G_s and G_i-coupled GPCRs have been implicated in stem cell pluripotency in hESC and hiPSC (Nakamura et al., 2009). Colony morphology correlates closely with the maintenance of pluripotency. G_i inhibition with pertussis toxin (PTX) results in hiPSC/ hESC colonies with a multi-layered appearance in contrast to a normal flat morphology, thereby preventing colony outgrowth (Nakamura et al., 2009). Proliferation, pluripotency and cell survival however, were unaffected by Gi inhibition. G_s activation on the other hand has been found to have no effect on colony morphology. While there is little evidence available in hPSCs, the activation of the Gsa-cAMP signalling pathway in mESCs contributes to the maintenance of transcription factor expression which is important for pluripotency (Layden et al., 2010). In addition, evidence exists for the involvement of the cAMP/PKA pathway in mESC self-renewal pathways (Faherty et al., 2007).

One of the key signalling pathways implicated in ESC self-renewal and pluripotency is the Wnt pathway. This signalling pathway can manifest in one of the three ways: (i) the canonical Wnt/β-catenin, (ii) Wnt/planar cell polarity (PCP) and (iii) Wnt/calcium pathways (Huang et al., 2004) (figure 2). Wnt ligands are lipid modified glycoproteins which bind to a Frizzled (FZD) receptors and a co-receptor; LRP 5/6. The co-receptor varies depending upon the signalling pathway.

In the past, while the Wnt/Ca^{2+} branch was recognized as the G protein-dependent pathway, the Wnt/β-catenin and Wnt/PCP signalling pathways were regarded as heterotrimeric G protein-independent. However, many important studies have more recently shown that heterotrimeric G proteins play a more global role in the general Wnt signalling pathway (Katanaev et al., 2005; Egger-Adam et al., 2008). Since the two intracellular scaffolding
proteins for FZD are heterotrimeric G proteins and Dishevelled (DVL), what is still not clear in this field is the nature of this interaction and signalling following an agonist binding. Depending on the intermediary involvement of the DVL this interaction can be either direct or indirect. In a direct interaction FZD can act as either (a) a guanine nucleotide exchange factor (GEF), catalysing the exchange of GDP for GTP on the $G_{\alpha}$ subunit, releasing GTP-$G_{\alpha}$ and $G_{\beta\gamma}$ or (b) a guanine dissociation inhibitor (GDI) sequestering GDP-$G_{\alpha}$ releasing $G_{\beta\gamma}$. However in the indirect model of interaction FZD may be acting through a higher order complex consisting of FZD, DVL and the heterotrimeric G protein complex, whereby the FZD-$G_{\alpha}G_{\beta}G_{\gamma}$ binding and signalling is via DVL (Nichols et al., 2013; Klipp et al., 2006; Schulte et al., 2007).

Expression of the pluripotency genes Sox-2, Nanog, OCT3/4 and brachyury are targets of the Wnt/β-catenin pathway (Sokol, 2011). hESCs have been shown to express Wnt1, members of the frizzled receptor family FZD1,3,6 and secreted frizzled related protein (SFRP) family (SFRP1, SFRP2, FRZB, SFRP4) (Walsh et al., 2003). The SFRP family act as antagonists to the Wnt pathway. There is contrasting evidence to support the role of Wnt signalling in hESC. Wnt3a and Wnt1 have been shown to stimulate hESC proliferation and maintain pluripotency via the canonical Wnt signalling pathway (Sato et al., 2004; Cai et al., 2007). In contrast, Wnt/β-catenin activation did not maintain the undifferentiated and pluripotent state morphology were observed after knockdown of FZD7 (Melchior et al., 2008a).

2.3. Cell migration
In addition to contributing to stem cell maintenance, the SDF1/CXCR4 pathway is important in endogenous stem cell trafficking during embryogenesis (McGrath et al., 1999; Miller et al., 2008). Activation of CXCR4 by SDF1 stimulates a number of pathways involved in motility, chemotaxis, adhesion and secretion, via activation of a number of signalling cascades including: adhesion, PI-3K-AKT, MEK-MAPK p42/44 and JAK/STAT (reviewed in (Kucia et al., 2004)). Both SDF1 and CXCR4 expression have been detected in mESCs and have been shown to be chemotactic for these cells (Guo et al., 2005). Priming of this pathway with sphingosine 1 phosphate (S1P) prior to the transplantation of cells enhanced cardiac and vascular remodelling in a rat model of pulmonary arterial hypertension (Yang, 2015). At the time of writing this review no evidence existed for the expression of SDF/CXCR4 in hESC or hiPSC.

2.4. Reprogramming somatic cells to iPSC
The modulation of the Wnt signalling pathway appears to play a role in reprogramming. Inhibition of the downstream signalling molecule, GSK3, has the potential to replace Klf4 in the Yamanaka reprogramming cocktail in murine cells (Lyssiotis et al., 2009). The use of a combination of different small molecules, including the GSK3beta inhibitor CHIR99021, has been reported to induced murine iPSC reprogramming in the presence of a single transcription factor (OCT4) (Li et al., 2011). Additionally, CHIR99021 in combination with an inhibitor of lysine-specific demethylase, has been used in the presence of OCT4 and Klf4 to successfully reprogram human keratinocytes (Li et al., 2009). Application of Wnt3a has been reported to enhance reprogramming in conjunction with Klf4/OCT4/SOX2 in the absence of c-myc (Marson et al., 2008). A cocktail of small molecules, including the cAMP activator forskolin, has also been shown to have the potential to replace OCT4 during murine iPSC-reprogramming (Hou et al., 2013). In addition to the expression of the Yamanaka transcription factors, morphological changes are necessary for cellular reprogramming.
3. GPCRs in cardiovascular differentiation

GPCRs have a fundamental role in early and late mesoderm formation during development and cardiovascular cell differentiation. To date, there are three platforms for cardiovascular cell differentiation: monolayer, embryoid body (EB) and microcarrier cultures. The efficiency of these methods depends on several factors including: (a) the biomolecules used (growth factors or small molecule inhibitors), (b) the condition of the hPSC culture expansion and (c) the activation or deactivation time of molecular signals in guiding the differentiation toward cardiovascular lineages (Chen et al., 2014). Differentiation is achieved through the coordination of diverse molecular pathways. Elucidation of the complex molecular signals that are evoked during hPSC differentiation have enabled specific targeting of their activities to enhance cell differentiation and promote tissue regeneration.

Earlier protocols for the production of cardiomyocytes (CM) (Zhang et al., 2009; Xu et al., 2002), endothelial cells (ECs) (Goldman et al., 2009a; Foldes et al., 2010) and vascular smooth muscle cells (VSMCs) (Dash et al., 2015; Ge et al., 2012) relied on EB formation, whereby hPSC undergo spontaneous differentiation following the formation of 3D, non-adherent structures. Although this method generated cells of the required lineages, it was relatively inefficient. Differentiation has been much improved in recent years with use of factors found to be involved in mesoderm formation in vivo. GPCR Wnt signalling molecules and non-GPCR fibroblast growth factor (FGF), bone morphogenetic protein 4 (BMP4) and Activin A are all widely used for cardiomyocyte differentiation (Laflamme et al., 2007; Yang et al., 2008). In all protocols, the concentrations and duration of each treatment depends on the platform as well as the hPSC line in use.

For endothelial cell differentiation growth factors frequently utilise FGF2, which has been shown to promote the formation of endothelial progenitors (Evseenko et al., 2010), and BMP-4, which acts to accelerate commitment to the endothelial lineage (Goldman et al., 2009b). Amongst the key pro-angiogenic growth factors, vascular endothelial growth factor (VEGF) is arguably the most important and has been demonstrated by multiple studies to dramatically increase the yield of endothelial cells during differentiation (Tatsumi et al., 2011; Adams et al., 2013). GPCR agonists such as thrombin and angiotensin II can directly modulate vascular remodelling and they can also act indirectly through the induction of VEGF (Richard et al., 2001).

Various differentiation protocols have been validated and replicated to differentiate pluripotent stem cells into vascular smooth muscle (VSMC) like cells with mature characteristics displaying cellular markers (smooth muscle α-actin, calponin) and an adult morphology (fibrous). In addition, they display similar contractile responses to agonists such as carbachol (Ge et al., 2012; Wanjare et al., 2013; Karamariti et al., 2013; Sinha et al., 2014; Dash et al., 2015). For generating smooth muscle cells, various limitations using the EB method of differentiation led researchers to develop improved protocols of VSMC differentiation from hiPSC using monolayers of extracellular matrix (ECM) proteins in the presence of PDGF subunit B homodimer (PDGF-BB) and transforming growth factor beta (TGF-β) (Karamariti et al., 2013; Wanjare et al., 2013) and heparin (Bajpai et al., 2012).

3.1. Frizzled Receptor

Wnt signalling is necessary for different steps of the cardiac development in embryonic stem cells, including myocardial specification, cardiac morphogenesis, and cardiac valve formation.
(Korkaya et al., 2009). It is believed the non-canonical Wnt pathway plays a key role in cardiac morphogenesis and affects the specification and expansion of cardiac progenitor cells (Korkaya et al., 2009). Hence, most of the latest protocols in the differentiation of hPSCs to CMs involve the use of various Wnt inhibitors and downstream molecules like GSK-3β.

Of the three stages of cardiomyocyte differentiation: mesodermal induction, cardiac progenitor generation and cardiomyocyte generation and maintenance, the initial step of mesoderm induction is induced by the activation of the TGF-β pathway (Xu, 2012; Watabe et al., 2009). This can be achieved by the use of growth factors, BMP4 and Activin A. An indirect activation of the TGF-β signalling pathway has been performed in vitro by using small molecules, such as GSK-3β inhibitors (CHIR99021 or BIO) which have an increasing effect on the endogenous levels of BMP2/4 (Minami et al., 2012; Lian et al., 2012). For the second stage of cardiac progenitor induction the TGF-β pathway has to be inactivated. This can be achieved by: (a) the removal of the activators and addition of growth factors including FGF2 and/or VEGF, which activate the ERK signalling pathway, or (b) the addition of small molecule Wnt inhibitors (KY02111, XAV939, DKK1, IWP-2 and IWR-1) (Chen et al., 2006). This results in the formation of the cardiac progenitor lineage from mesodermal cells and inhibits the development of smooth muscle and endothelial cell lineages (Woll et al., 2008; Yang et al., 2008). The final stage of CM generation and maintenance, which takes place from day 8 is also found to be dependent on the inhibition of the Wnt/β-catenin signalling pathway (Gessert et al., 2010). It can therefore be concluded that Wnt signalling plays a biphasic role in human cardiogenesis, being both activated during the early phase and inhibited during the late phase of cardiac differentiation (Lian et al., 2012).

During foetal growth the compact myocardium proliferates more rapidly when compared to the trabecular myocardium in luminal regions of the heart (Jeter, Jr. et al., 1971; Luxan et al., 2013). The proliferation of foetal cardiomyocytes in this region is necessary for the correct morphogenesis of ventricular myocardium, trabeculae and chamber cavities. It has recently been shown that this regional expansion of ventricular myocytes is regulated by the Wnt/β-catenin pathway. The increase in the ventricular proliferation is maintained until birth. This foetal Wnt signalling pathway is re-expressed upon myocardial infarction and induced ischemic heart injury in mice (Buikema et al., 2013a; Buikema et al., 2013b). Hence, it has been suggested that in adult myocardium Wnt/β-catenin may play a role in endogenous cardiac repair; however, the exact role of this pathway in the adult cardiac homeostasis is not yet known (Oka et al., 2007; Oerlemans et al., 2010).

In addition, the production of pluripotent stem cell-derived endothelial cells (PSC-EC) has also been shown to be dependent on small molecule activation of canonical Wnt signalling. This was demonstrated to be an effective mechanism using a 2D culture system, even in the absence of exogenous VEGF (Lian et al., 2014). The canonical Wnt ligands, Wnt7a and Wnt7b, have been implicated in blood-brain barrier (BBB) development in vivo (Daneman et al., 2009). In order to generate human BBB-ECs, the Wnt pathway was targeted in differentiating hPSCs (Lippmann et al., 2012). A Wnt target gene called Stimulated by retinoic acid 6 (STRA6) which acts as a vitamin A transporter is found in the BBB (Szeto et al., 2001). It is highly expressed in adult brain endothelial cells in comparison to lung or liver cells, and is up-regulated during the course of BBB cell differentiation (Lippmann et al., 2012).

3.2. Angiotensin Receptor
Angiotensin receptors are members of the GPCR family and are composed of two main
types; angiotensin receptors I and II (AT₁ and AT₂) which exhibit similar affinities for
angiotensin II (Ang II) (de Gasparo et al., 2000). The activated AT₁ binds to G_{q/11} and G_{q0} to
activate phospholipase C and increase the cytosolic Ca^{2+} concentration, whilst AT₂ exerts its
effect via coupling to the G_{12/3} components of the heterotrimeric G-proteins (Higuchi et al.,
2007). Activated AT₁ and AT₂ have mutually counteracting haemodynamic effects in the
cardiovascular system. AT₁ is believed to be responsible for the contractile response while
AT₂ is involved in the relaxation response to Ang II (Batenburg et al., 2004). Ang II
promotes the differentiation of mESC-CM through AT₁ (Wu et al., 2013). Currently no role
in human cardiovascular differentiation has been described. AT₁ and AT₂ are expressed on
human haemangioblasts. The differentiation into endothelial progenitors can be influenced by
modulating the signalling through these receptors. ACE activity is required for
haemangioblast expansion. AT₁- or AT₂ specific inhibitors dramatically augment endothelial
differentiation (Zambidis et al., 2008).

3.3. Apelin Receptor
This receptor, also known as Angiotensin receptor like 1 (AGTRL1 or APJ) is a member of
the GPCR family that binds apelin (APLN) (Tatemoto et al., 1998; Lee et al., 2000) and
ELABELA/ Toddler (Chng et al., 2013a; Pauli et al., 2014). APJ is coupled to G_{q} and/or G_{q4}
and is expressed in the mesodermal cells of the secondary heart field in mouse embryo. It
couples extracellular signalling with chromatin modifications in pluripotent stem cell
cardiomyogenesis (D’Aniello et al., 2013). During hESC differentiation, APJ marks
mesodermal precursors (Vodyanik et al., 2010). While on adult cardiomyocytes, the
expression of this receptor is a potent regulator of contractility (Szikodi et al., 2002; Berry et
al., 2004; Ashley et al., 2005); on early embryonic cells it is believed to regulate the
migration of progenitor cells fated for cardiomyocyte differentiation (Scott et al., 2007; Zeng
et al., 2007). Hence, Apelin has been used in the differentiation of both mouse and human
ESCs to cardiomyocytes in combination with mesodermal differentiation factors including
BMP4, bFGF and Activin A. Using an EB differentiation method and by administering these
factors in a specific temporal sequence, it has been shown that apelin can indeed promote
cardiac differentiation and lead to earlier beating EBs when compared to controls (Wang et
al., 2015). We and others have shown that APJ and one of its ligands apelin have an
important regulatory role in angiogenesis (Scott et al., 2007). A second ligand elabela (or
Toddler) has been recently discovered which is required for the normal development of
vasculature through activation of APJ. Elabela/APJ signalling pathway was shown to be
functional in the human system as well (Chng et al., 2013a; Wang et al., 2015). To date, no
published data is available for the new ligand in hPSCs.

3.4. Lysophospholipid Signalling
Lysophospholipid signalling is important for vascular development and maturation, but in
vitro stem cell models are currently lacking. Knockout mice of S1P₁ (G_{i}-coupled receptor for
sphingosine-1 phosphate) has been showing high lethality at E12.5 (Soriano, 1999). This has
been attributed to the necessary function of endothelial cells (Kataoka et al., 2003) and the
receptor has also been found to be essential for vascular maturation (Liu et al., 2000).
Furthermore in vivo studies have shown that S1P protein synergises with FGF-2 and VEGF
in angiogenesis and vascular maturation through S1P₁ (Garcia et al., 2001). While
S1P₃ couples directly to the G, pathway, the other receptor isoforms known also as endothelial
differentiation gene 3, 5 (Edg-3 and -5) stimulate G₁, G₄, and G₁₃ pathways (Windh et al.,
1999; Ancellin et al., 1999).
3.5. Protease-activated receptor-1
Protease-activated receptor-1 (PAR-1) is one of the four members of the PAR subfamily of GPCRs, which are highly expressed in platelets as well as endothelial cells, myocytes and neurons (Macfarlane et al., 2001). PAR-1 is activated by serine proteases including thrombin, whereby the N-terminus of the receptor is cleaved and this in turn acts a tethered ligand activating the receptor. As PARs are involved in maintaining haemostasis and thrombus formation in atherosclerotic vessels, these are being tested as drug targets (Sambrano et al., 2001). As a member of the receptor family, PAR-1 was shown to play a role in embryonic development (Griffin et al., 2001), partially via modulation of downstream signalling proteins such as the heteromeric G-protein subunit Gα13 (Ruppel et al., 2005). The role in hPSC differentiation remains to be defined.

3.6. Adrenergic Receptors
Adrenergic receptors can be broadly divided into alpha (α-AR) and beta (β-AR) receptors. The β-ARs have been shown to have a role in cardiomyocyte differentiation (Yan et al., 2011). β1-ARs couple to stimulatory G proteins (Gs). Once stimulated, Gs-proteins interact with the enzyme adenylyl cyclase (AC), which in turn increases the production of cAMP, β2-ARs and β3-ARs can also couple to the inhibitory G (Gi) protein (Gauthier et al., 1996; Gong et al., 2000). β2-AR Gi pathways decrease AC activation and cAMP production as well as the downstream phosphorylation of cardiac proteins including troponin I, myosin-binding protein C and L-type calcium channels. The net result opposes the action of the Gi, resulting in reduced contraction of the cardiac myocytes (Xiao et al., 1995; Woo et al., 2012). Further studies in mESCs have shown that β-ARs play a role in ESC-CM differentiation via ERK and p38 activation using β-AR agonists. β1-ARs and β2-ARs have been found at different stages of cardiac differentiation both at mRNA and protein levels. The expression of β1-AR is lower than β2-AR until day 7. After day 7 it increases gradually, reaching a peak at day 14, and remains at a high level until day 21. In contrast, β2-AR is expressed at a high level even before differentiation, with no obvious change after inducing cardiac differentiation. It is therefore believed that β2-AR might be the predominant subtype during the early stage of differentiation, while β1-AR might be the predominant subtype for the late stage of cardiac differentiation (Yan et al., 2011).

4. GPCRs in pluripotent stem cell cardiovascular derivatives
In recent years, the ability to derive human cardiovascular cells from pluripotent stem cells, which have unlimited renewal capacity, has generated considerable interest. hPSC-derived cardiovascular derivatives have the potential to reduce the use of animal models and provide more physiologically relevant models of disease. They can be produced in quantities that are suitable for use in medium to high throughput screens, and platforms are being developed to measure their various functional outputs, including calcium transients, contraction, tubule formation and cytotoxicity/signalling (Mioulane et al., 2012; Mercola et al., 2013; Stoehr et al., 2014; Simons et al., 2015). The relative ease of production and commercial availability further enhances their appeal for pharmaceutical screening and organ repair.

4.1. Human pluripotent stem cell-derived cardiomyocytes
4.1.1. Alpha-adrenergic receptors
α-ARs (α1a, α1b, α1d) regulate the cardiovascular system by activating the Gαq pathway. Once activated, Gαq activates phospholipase C (PLC), which causes an increased myo-inositol-1,4,5-trisphosphate level and subsequent increase in calcium release from the endoplasmic reticulum (Exton, 1985; Salazar et al., 2007). These receptors are primarily thought to regulate blood pressure, inotropy and hypertrophy by cross talk between the α-AR subtypes
and also with β-ARs (Salazar et al., 2007). For example, overexpression of the α1A-AR increases cardiac contraction but not hypertrophy (Lin et al., 2001) and overexpression of α1b-AR results in a decreased response to β-AR stimulation by isoprenaline left ventricular (LV) contractility, potentially as a result of additional Gi coupling (Akhter et al., 1997). Additionally, a deficiency in the α1b-AR receptor results in a blunted blood pressure response to the α1-AR receptor agonist phentolamine (PE) (Cavalli et al., 1997). Alpha-2-adrenergic receptors (α2-AR) are Gi-coupled receptors and oppose the action of Gs signalling by inhibiting AC and therefore cAMP production and the various downstream sequelae (Salazar et al., 2007). α2-ARs are presynaptic and suppress presynaptic noradrenaline release and their role is to oppose the sympathetic stimulation of β1-AR, β2-AR and α1-ARs during increased adrenergic stimulation. Their importance was shown with higher incidences of heart failure in patients with genetic polymorphisms resulting in the loss of function of α2-ARs (Small et al., 2002).

The expression of α-ARs in hPSC-CMs, as reported by our own group shows an early transient up-regulation during differentiation followed by a rapid stable down-regulation of ADRA1A in hiPSC-CM and hESC-CM. Conversely ADRA1B was found to be increased in an apparently compensatory manner. Other subtypes of α-AR namely ADRA1D and ADRA2C have also been shown to be present in these cells, but the overall expression of these receptors and their G-proteins; Gi, Gβ1, and Gγ2 is believed to be insufficient for the hypertrophic response to PE (Foldes et al., 2014). However, when investigating the exact localisation of α1-ARs in adult cardiomyocytes, recent studies found them expressed in the nuclei rather than just the sarcolemma itself: this may contribute to the differences observed in the response levels of various cell types to PE (Wu et al., 2015b).

4.1.2. Beta-adrenergic receptors

There are three main types of β-ARs present in the human cardiovascular system; β1-ARs are the most abundant accounting for 75-80% in healthy human hearts (Rockman et al., 2002); with β2-ARs and β3-ARs making up the remainder. β1-ARs primarily modulate the inotropic and chronotropic responses of the human heart. Once activated, stimulatory Gs-proteins interact with AC, which in turn increases the production of cAMP. The increased levels of cAMP result in increased binding to protein kinase A (PKA) and subsequent phosphorylation of many myocyte proteins (troponin I, voltage L-type calcium channels, cardiac ryanodine receptor) involved in cardiac contractility (Rockman et al., 2002; Xiang et al., 2003). The importance of β1-ARs in cardiovascular regulation has been shown in β1-AR knockout mice. Many did not survive past embryo stage and if they did, an increased heart rate in response to isoprenaline was found to be absent while the inotropic response to exercise/agonist stimulation was still present (Rohrer et al., 1996). On the other hand, transgenic mice with overexpression of β1-ARs develop marked hypertrophy and increased contractility initially, but this is soon followed by the onset of heart failure (Engelhardt et al., 1999). β2-ARs have some similarities with β1-ARs in regulating contractility by utilizing Gs-proteins and the AC pathway with the eventual downstream release of calcium from L-type Ca2+ channels (Salazar et al., 2007). They differ in that β2-ARs can additionally couple to Gq (Daaka et al., 1997). Mice with overexpression of the β2-AR at 60-fold exhibited enhanced basal cardiac function without increased mortality when followed for 1 year. However, after 100-fold or more overexpression they developed a fibrotic cardiomyopathy and heart failure which increased in severity with overexpression level (Liggett et al., 2000). Knockout mice, however, display a relatively normal phenotype but develop a higher degree of hypertension in response to stress (exercise, adrenaline) when compared to control mice (Chruscienski et al., 1999). This may indicate the importance of the inhibitory G-coupled protein pathway in
prolonged adrenergic stimulation (Salazar et al., 2007). βARs are expressed the least in the 2 heart and their role in cardiovascular regulation is a little less certain with inotropic effects in 3 response to agonists in mice overexpressing human βARs; however, a negative inotropic 4 response in the human heart has been seen (Gauthier et al., 1996; Kohout et al., 2001). βARs 5 are also up-regulated in human heart failure (Moniotte et al., 2001). Studies on hPSC-CMs 6 have shown that β-AR responses are well developed in cardiomyocytes derived from 7 hESCs and hiPSCs (Ali et al., 2004; Dambrot et al., 2014a). Furthermore the expression of 8 both β1-AR and β2-AR has also been established, with β1-AR being suggested as the 9 predominant subtype for the late stage of cardiac differentiation (Wu et al., 2013; Wu et al., 10 2015a).

4.1.3. Angiotensin, muscarinic and adenosine receptors
Other GPCRs also present on hPSC-CMs are ATs and muscarinic receptors as shown by 13 expression studies and agonist responses in these cells. Muscarinic receptors reduce 14 spontaneous beating rate in hPSC-CM from an early time after differentiation, although the 15 muscarinic receptor subtype has not been delineated (Brito-Martins et al., 2008). Adenosine 16 can produce similar effects through the A1-R in adult ventricular or atrial cardiomyocytes 17 (Headrick et al., 2013) but to date no published data exists for hPSC-CMs. We have shown 18 previously that angiotensin acting via Gq can produce only a small increase in cell size in 19 hESC-CM despite a robust increase in the expression of both atrial natriuretic factor and B- 20 type natriuretic peptide (ANF and BNP) (Foldes et al., 2008; Foldes et al., 2014).

4.1.4. Endothelin receptors
Endothelin receptors, specifically the endothelin-A (ET_A) receptor, are subtypes of receptors 26 involved in cardiac remodelling/hypertrophy. ET_A is expressed in the cardiovascular system 27 and has a plethora of roles including vasoconstriction, tachycardia, positive inotropy and 28 hypertrophy (Concas et al., 1989; Salazar et al., 2007; Bupha-Intr et al., 2012). In addition, 29 ET receptors are up-regulated in chronically failing human hearts (Asano et al., 2002; Salazar 30 et al., 2007). In hPSC-CM, ET_A induces hypertrophic gene expression; such as BNP and 31 ANF (Carlson et al., 2013; Foldes et al., 2014). The exact downstream signalling mechanisms have not yet been published.

4.1.5. Disease modelling with hPSC-CM
Predominant manifestations of pathology investigated in hPSC-CM are acute, including 39 depressed contraction, electrophysiological alterations and arrhythmia, or longer-term, such 40 as aberrant morphology, hypertrophy and increased susceptibility to cell death. While the 41 acute characteristics have strong superficial similarities to adult cardiomyocytes, a clear 42 difference in long term viability is seen in the prolonged survival in culture of hPSC-CM (> 1 43 year) compared to adult cells (~2 days). This of course is one of the main attractions of 44 hPSC-CM as a model system. Although proliferation rates in hPSC-CM are initially far 45 higher than in adult cardiomyocytes, these drop rapidly around one month after 46 differentiation, as the sarcomere structure develops (Foldes et al., 2011). Morphology is 47 initially less organised, but can develop with time or physical cues. The nature of the 48 differences between adult and hPSC-CM phenotypes and the consequent limitations for 49 modelling are discussed further below.

One pathological process where GPCR signalling plays a prominent role is cardiac 51 hypertrophy. This is an adaptive response and is characterised by a thickening of cardiac 52 myocytes. Physiological hypertrophy occurring in pregnancy and athletes is not detrimental 53 and results in normal or enhanced heart function. In contrast pathophysiological hypertrophy,
which can be caused by pressure overload in response to hypertension, myocardial infarction or other inherited conditions, leads to cardiac dysfunction and increased mortality. Approaches have been taken to model hypertrophy in vitro using hPSC-CM.

The predominant α-ARs in the myocardium are α1-ARs (Bruckner et al., 1985) and stimulation with catecholamines induces pathological cardiac hypertrophy (Rokosh et al., 1996; Zhong et al., 1999). We have previously reported an increase in cell size in hESC-CM in response to the α-AR agonist PE (Foldes et al., 2011), attributed to activation of p38 MAPK signalling pathways. As described above, α1A-AR gene expression was lost upon differentiation in hESC-CM (and hiPSC-CM), while α1B-AR was up-regulated and mediated the hypertrophic response (Foldes et al., 2014). In addition ET1, Ang II and cyclic stretch also increased cell size in hESC-CM (Foldes et al., 2011; Foldes et al., 2014) with corresponding increases in ANF expression. β2-AR stimulation did not induce cellular hypertrophy.

Hypertrophic responses in hiPSC-CM remain controversial. In contrast to hESC-CM, we found hiPSC-CM to be unresponsive to PE, with cell size (assessed by high content automated microscopy) and ANF expression remaining unchanged (Foldes et al., 2014). In addition, ET-1 and Ang II did not produce significant increases in cell size and correspondingly increased ANF and BNP expression was only seen in response to ET1. Hypertrophic modelling in commercially available hiPSC-CM assays have been described which rely on detection of ANF expression in response to ET1 (Aggarwal et al., 2014). In other studies, mild increases in hiPSC-CM size (~10% or less) have been seen with PE, and up to 25% with ET-1 (Carlson et al., 2013; Tanaka et al., 2014). In addition, enhanced myofibrillar disarray and nuclear factor of activated T-cells (NFAT) nuclear translocation were also reported (Zhi et al., 2012). There is conflicting data for the presence of cardiomyocyte hypertrophy in response to β-adrenergic stimulation. We found no increase in hiPSC-CM size (Foldes et al., 2014), whereas Zhi and colleagues found the opposite (Zhi et al., 2012). It has been reported that serum containing media causes hypertrophy in hESC-CM and hiPSC-CM, which could explain the lack of cellular hypertrophy in response to hypertrophic stimuli in some studies (Dambrot et al., 2014b). This was found not to be the explanation in our study (Foldes et al., 2014); the difference between hESC-CM and hiPSC-CM was caused rather by an imbalance in anti-hypertrophic signalling. It was also found that a combination of inhibitors could restore the PE response in hiPSC-CM.

A number of hiPSC-CM disease models have a hypertrophic phenotype, including LEOPARD syndrome and hypertrophic cardiomyopathy (HCM). Patient-derived HCM hiPSC-CM exhibit increased basal cell size compared to controls ((Lan et al., 2013; Tanaka et al., 2014), β-AR stimulation exacerbates cellular hypertrophy in HCM cells (Lan et al., 2013). A hiPSC-CM model of LEOPARD of syndrome exhibits a hypertrophic phenotype, displaying increased cell size and nuclear located NFAT (Carvajal-Vergara et al., 2010). It still remains to be determined whether HCM patient-derived cardiomyocytes or control cells treated with hypertrophic stimuli are the best model to use for the study of hypertrophy. Furthermore, a greater understanding of hypertrophic signalling in hPSC-CM is required to ensure conclusions drawn from these models are physiologically relevant.

In addition to hypertrophy, disease models have also provided further insight into pathological mechanisms involving GPCRs (table 3). Patient-derived dilated cardiomyopathy (DCM) hiPSC-CMs display an increased susceptibility to stress. Desensitisation of the β-AR response was observed in DCM hiPSC-CM both basally and in response to acute
noradrenaline treatment (Sun et al., 2012). This goes against the current understanding of β-AR desensitisation as an acquired characteristic of prolonged sympathetic stimulation in the heart failure patient. Either the troponin mutation has some mechanistic link to the control of β-AR function, or there is a co-inherited β-AR variant in this group of patients; either option is intriguing. In addition, long term β-AR stimulation resulted in sarcomeric disorganisation and decreased inotropic and chronotropic responses. In patient-derived HCM hiPSC-CM, β-adrenergic stimulation also exacerbated the observed abnormal calcium handling and arrhythmia (Lan et al., 2013). In long QT syndrome (LQTS2 and LQTS1) hiPSC-CM models, arrhythmia was observed in response to β-adrenergic stimulation, which could be prevented using β-AR blockers (Tseng et al., 2006; Matsa et al., 2011). This correlates with clinical observations, where β-AR blockers are routinely used to treat such conditions. The majority of these disease models originate from patient derived-hiPSC, but the trisomy 21 model described by Bosman and co-workers utilises patient hESC-derived cardiomyocytes (Bosman et al., 2015). In this study trisomic cells showed an increased β-AR response to isoprenaline in comparison to euploid control (Bosman et al., 2015).

4.2. Vascular derivatives

ECs form a single-cell monolayer lining the blood vessels. Their essential functions include the ability to regulate vascular tone, vascular permeability, platelet function and inflammatory responses (Michiels, 2003). ECs are involved in inflammation and interact closely with leukocytes. GPCRs expressed in these cells play a key role in sensing the presence of chemoattractants, transducing signals that lead to the production of cytokines and regulating vascular permeability (table 2). ECs are therefore critical for vascular homeostasis, and cellular dysfunction is strongly associated with an increased risk of cardiovascular events (Lerman et al., 2005). Generating novel ECs is a powerful in vitro technique to study cellular responses under various culture conditions and to develop constructs for tissue engineering. PSC-ECs are suggested to have many of the properties of endogenous ECs and their phenotypes are being investigated to determine whether characteristics of vascular disease can be reproduced in vitro.

VSMCs have a plethora of roles in the cardiovascular system from producing extracellular matrix proteins which provide elasticity and the ability to withstand high circulating pressures to being involved in arterial repair and regulation of vascular tone. They are primarily contained in the media layer of blood vessels (Lacolley et al., 2012). The sympathetic nervous system regulates vascular tone and primarily acts on VSMCs via ARs. β2-ARs agonists cause vasodilation and hypotension while α-AR (α1,2) agonists cause vasoconstriction (Barbato, 2009). Like PSC-ECs, PSC-VSMCs are an interesting area of research and are being used in tissue engineering strategies as well as an avenue for studying human diseases of the vascular smooth muscle (Xiang et al., 2003; Salazar et al., 2007). Little has been reported regarding GPCR function in PSC-VSMC apart from a contractile response to carbachol, and even then the muscarinic subtype was not identified (Dash et al., 2015).

4.2.1. CXCR4 receptor

The SDF-CXCR4 axis plays an important role in stem cell trafficking, chemotaxis, engraftment, and therapeutic angiogenesis (Hoggatt et al., 2013). CXCR4 is required for normal vascularization of the small intestines and mesentery branching (Tachibana et al., 1998). Murine iPSC-ECs express abundant CXCR4 protein intracellularly, but not on the cell surface. When iPSC-ECs were systemically delivered, these did not home to the site of hindlimb ischemia in vivo. It was also noted that iPSC-ECs did not respond to chemotactic gradients of SDF. This overall suggests that these cells retain an immature phenotype (Huang...
et al., 2013). Because GPCR proteins are typically expressed at low levels in endogenous tissues, the use of proteomic profiling approaches for identifying further endothelial-specific GPCRs proves problematic.

4.2.2. Angiotensin receptor
Ang II stimulates VSMC contraction and aldosterone release with consequent sodium retention. It also stimulates the production of ECM proteins and is pro-inflammatory (Wollert et al., 1999). Ang II is the main mediator of this pathway and signals primarily through the AT₁ receptor (Touyz et al., 2000). AT₁ receptors are upregulated in response to hypertensive rats and hypertrophic stimuli (Suzuki et al., 1993). In contrast, they are down-regulated in systolic heart failure (Rogg et al., 1996). Overexpressing AT₁A in mice resulted in hypertrophy and fibrosis of myocardial tissue (collagen deposition) (Paradis et al., 2000). AT₁A deficient mice, however, were more resistant to the effects of myocardial ischaemia with less ventricular dilatation and fibrosis and a better recovery in LV function four weeks after infarction (Harada et al., 1999). To date the effect of Angiotensin receptors and stem cells has only been investigated in mice. AT₁R stimulation has been found to enhance not only the proliferation but also the differentiation of undifferentiated pluripotent stem cells into mesodermal progenitor cells (Ishizuka et al., 2012).

4.2.3. Endothelin receptor
The endothelin pathway also has a regulatory role in hPSC-ECs. Differentiation of hESC into endothelial cells (hESC-ECs) can be a potential source of cells and endothelial factors for ischaemic diseases by supporting angiogenesis and vasculogenesis (Burdon et al., 1999; Lesman et al., 2010). Protocols for new ECs from hPSC generated cells with high initial clonal proliferative potential with self-repopulating potential and in vivo vessel-forming ability have been devised (Ingram et al., 2004; Foldes et al., 2010; James et al., 2010). However, a number of differences between hPSC-derived cells and adult endothelial cells have been noted. For example, we found that hESC-EC failed to release the GPCR ligand endothelin-1 (ET-1) at levels comparable to human aortic endothelial cells or to blood outgrowth endothelial cells (Reed et al., 2014). However, in a separate study it was demonstrated that hiPSC-EC were able to upregulate ET-1 expression in response to atheroprone flow (Adams et al., 2013).

4.2.4. Disease modelling with PSC-ECs and PSC-VSMC
In contrast to myocytes, limited studies using disease models in EC and VSMC are available. They have been used for vascular repair: the first model using ESC-ECs has recently been evaluated in myocardial infarction and hindlimb ischemia as a therapeutic option to promote angiogenesis and neovascularization (Cho et al., 2007; Yu et al., 2009). iPSC-ECs derived from diet-induced obese mice exhibit endothelial dysfunction and may not be suitable for therapeutic transplantation in a hindlimb ischemia model. Furthermore, the administration of statins reversed endothelial dysfunction both in vitro and in vivo (Gu et al., 2015).

Recently, hiPSC lines were differentiated from patients with supravalvular aortic stenosis (William’s syndrome). The VSMCs displayed a blunted maturation profile with fewer organized smooth muscle α-actin filament bundles networks and also had a higher proliferation rate (a hallmark of the disease). Reversion to a wild type phenotype was achieved by the addition of recombinant elastin protein or enhancing small GTPase RhoA signalling (Ge et al., 2012). In addition, hiPSC-VSMCs have been derived from patients with Hutchinson-Gilford progeria syndrome (HGP), a disease carrying a lamin A mutation and increased progerin levels, leading to premature aging and early mortality by myocardial
infarction/stroke. The differentiated VSMCs contained high levels of progerin and also exhibited a new phenotype, calponin-1 staining inclusion bodies in the cytoplasm. Additionally, the VSMCs had nuclear abnormalities and increased DNA damage compared to controls (Zhang et al., 2011). To date, the GPCR related signalling of these human diseases have not been clarified.

5. Summary: focussed targeting of GPCR signalling in human cardiovascular system

hPSCs show potential as a platform for both studying disease as well as an autologous source of cells for possible transplantation therapy (Lee et al., 2010a). Particularly for cardiomyocytes, where adult cells are difficult to manipulate in culture and options for cell lines are severely limited, the advent of disease-specific hiPSC-CM represents a great step forward. Differentiation methods are improving in efficiency and reproducibility. However, models should never be accepted uncritically, and a more sophisticated dissection of their fidelity has begun to appear. One major limitation is the greater resemblance of hPSC-CM to immature cardiomyocytes, although this may also be a reflection of the general differences induced by 2D cell culture. This could present a problem for models of late onset diseases. A wide array of approaches are being undertaken to improve maturation of these cells in an attempt to provide better models of disease. These include; prolonged time in culture (Ivashchenko et al., 2013), application of triiodothyronine (T3) (Ivashchenko et al., 2013; Yang et al., 2014; Ribeiro et al., 2015; Lee et al., 2010b), manipulation of culture substrate (Rao et al., 2013; Tallawi et al., 2015), 3D culture (Schaaf et al., 2011) and long term electrical pacing (Lieu et al., 2013; Hirt et al., 2014). hPSC-EC also display an immature phenotype (Huang et al., 2013), which still requires further investigation.

Another limitation is the use of correct controls, particularly for disease models. Obtaining control material from familial relatives of patients can prove difficult, which makes drawing solid conclusions from these disease models problematic. Gene editing technology approaches, such as the clustered regularly interspaced short palindromic repeats (CRISPR) system and zinc finger nucleases (ZFN) have arisen as useful tools to generate control lines on the same genetic background as the diseased cells. Alternatively, recreation of disease causing mutations in wild type cell lines using these technologies is an option and will allow multiple mutations to be compared in a more controlled manner. Additionally, identifying pharmacologically-relevant phenotypes in these models is important. It also remains to be determined whether monogenic disease and pharmacological models are comparable in cardiovascular diseases. The expected phenotype is not always present, for example in cardiac hypertrophy (Foldes et al., 2014), which may be a limitation of the in vitro models. Modelling conditions with a broader tissue-based phenotype including scar formation, fibrosis and tissue disarray are also not possible using hPSC-CM in 2D culture, although the reconstruction of 3D tissue models may allow advances in this area. In particular, a greater understanding of GPCR signalling in hPSC-CM is needed to ensure accurate disease modelling and to determine suitability for use in pharmaceutical compound screening. More focussed investigation into the expression profile and functional characterisation of GPCRs in PSC-derived cardiovascular cells is required to establish their resemblance to in vivo models.

Acknowledgments

This paper was supported by the British Heart Foundation and Fondation Leducq Shapeheart Network.

Non-Standard Abbreviations
<table>
<thead>
<tr>
<th></th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7TM receptors, seven-transmembrane domain receptors</td>
</tr>
<tr>
<td>2</td>
<td>α-ARs, α-adrenergic receptor</td>
</tr>
<tr>
<td>3</td>
<td>AC, adenylyl cyclase</td>
</tr>
<tr>
<td>4</td>
<td>ACE, angiotensin converting enzyme</td>
</tr>
<tr>
<td>5</td>
<td>ANF, atrial natriuretic factor</td>
</tr>
<tr>
<td>6</td>
<td>APC, adenomatosis polyposis coli</td>
</tr>
<tr>
<td>7</td>
<td>AT₁, angiotensin receptor 1</td>
</tr>
<tr>
<td>8</td>
<td>β-AR, β-adrenergic receptor</td>
</tr>
<tr>
<td>9</td>
<td>BBB, blood-brain barrier</td>
</tr>
<tr>
<td>10</td>
<td>BMP4, bone morphogenetic protein 4</td>
</tr>
<tr>
<td>11</td>
<td>BNP, B-type natriuretic peptide</td>
</tr>
<tr>
<td>12</td>
<td>cAMP, 3’,5’-Cyclic adenosine monophosphate</td>
</tr>
<tr>
<td>13</td>
<td>CK1a, casein kinase 1a</td>
</tr>
<tr>
<td>14</td>
<td>CRISPR, clustered regularly interspaced short palindromic repeat</td>
</tr>
<tr>
<td>15</td>
<td>DCM, dilated cardiomyopathy</td>
</tr>
<tr>
<td>16</td>
<td>DMD, Duchenne muscular dystrophy</td>
</tr>
<tr>
<td>17</td>
<td>DVL, Dishevelled</td>
</tr>
<tr>
<td>18</td>
<td>EC, endothelial cell</td>
</tr>
<tr>
<td>19</td>
<td>ECM, extracellular matrix</td>
</tr>
<tr>
<td>20</td>
<td>ERK1/2, extracellular signal-regulated kinases 1/2</td>
</tr>
<tr>
<td>21</td>
<td>ETₐ, endothelin receptor A</td>
</tr>
<tr>
<td>22</td>
<td>FGF, fibroblast growth factor</td>
</tr>
<tr>
<td>23</td>
<td>FZD, Frizzled receptor</td>
</tr>
<tr>
<td>24</td>
<td>GDP, guanosine diphosphate</td>
</tr>
<tr>
<td>25</td>
<td>Gi, guanine-coupled inhibitory protein</td>
</tr>
<tr>
<td>26</td>
<td>GSK3, glycogen synthase kinase 3</td>
</tr>
<tr>
<td>27</td>
<td>GPCR, G-protein coupled receptors</td>
</tr>
<tr>
<td>28</td>
<td>Gs, guanine-coupled stimulatory protein</td>
</tr>
<tr>
<td>29</td>
<td>GTP, guanosine triphosphate</td>
</tr>
<tr>
<td>30</td>
<td>HCM, hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>31</td>
<td>hESC, human embryonic stem cells</td>
</tr>
<tr>
<td>32</td>
<td>HF, heart failure</td>
</tr>
<tr>
<td>33</td>
<td>HGP, Hutchinson-Gilford progeria syndrome</td>
</tr>
<tr>
<td>34</td>
<td>hPSC, human pluripotent stem cells</td>
</tr>
<tr>
<td>35</td>
<td>JNK, c-Jun amino (N)-terminal kinase</td>
</tr>
<tr>
<td>36</td>
<td>IP3, inositol-1,4,5-triphosphate</td>
</tr>
<tr>
<td>37</td>
<td>LEF lymphoid enhancer factor</td>
</tr>
<tr>
<td>38</td>
<td>LPA, lysophosphatidic acid</td>
</tr>
<tr>
<td>39</td>
<td>LQT, long QT syndrome</td>
</tr>
<tr>
<td>40</td>
<td>mESC, murine ESC</td>
</tr>
<tr>
<td>41</td>
<td>MI, myocardial Infarction</td>
</tr>
<tr>
<td>42</td>
<td>NFAT, nuclear factor of activated T-cells</td>
</tr>
<tr>
<td>43</td>
<td>PAF, platelet activating factor</td>
</tr>
<tr>
<td>44</td>
<td>PDGF, platelet derived growth factor</td>
</tr>
<tr>
<td>45</td>
<td>PE, phenylephrine</td>
</tr>
<tr>
<td>46</td>
<td>PI3-K, phosphoinositide 3-kinase</td>
</tr>
<tr>
<td>47</td>
<td>PKA, protein kinase A</td>
</tr>
<tr>
<td>48</td>
<td>PKC, protein kinase C</td>
</tr>
<tr>
<td>49</td>
<td>PLC, phospholipase C</td>
</tr>
<tr>
<td>50</td>
<td>PP2A, protein phosphatase 2A</td>
</tr>
</tbody>
</table>
PSC-EC, pluripotent stem cell-derived endothelial cells
PTX, pertussis toxin
S1P, sphingosine 1 phosphate
SDF1, stromal cell derived factor 1
SFRP, secreted frizzled related protein
SM, smooth muscle
T3, triiodothyronine
TCF T-cell factor
TGF-β, transforming growth factor β
VEGF, vascular endothelial growth factor
VSMC, vascular smooth muscle cell
ZFN, zinc finger nuclease

Conflict of interest statement
None

Author contributions
NFD, NH, RJ, GF contributed to the conception of the review and wrote the manuscript. SEH critical revised and final approved the review.

Short biography of the corresponding author
Sian Harding is Professor of Cardiac Pharmacology at the National Heart and Lung Institute, Imperial College. She obtained her Ph.D. in Pharmacology from King's College, London in 1981, and since then the primary focus of her work has been cardiomyocyte function in the failing heart. This has extended to gene therapy to modulate cardiomyocyte function, and she is Scientific PI for a UK clinical trial on myocardial gene therapy. More recently the scope has extended to the characterization of cardiomyocytes derived from pluripotent stem cells, and their use in cardiac repair, tissue engineering and drug discovery. She has been elected Fellow of both the American Heart Association and the European Society of Cardiology. Prof Harding is now Director of the Imperial British Heart Foundation Cardiovascular Regenerative Medicine Centre.

Reference List


Berry, M.F., Pirolli, T.J., Jayasankar, V., Burdick, J., Morine, K.J., Gardner, T.J. et al. (2004). Apelin has in vivo inotropic effects on normal and failing hearts. *Circulation* **110**, II187-II193.10.1161/01.CIR.0000138382.57325.5c [doi];110/11_suppl_1/II-187 [pii]


McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K. et al. (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur. Heart J.* **33**, 1787-1847.ehs104 [pii];10.1093/eurheartj/ehs104 [doi]


Yang, H. The Therapeutic Effects of Human Mesenchymal Stem Cells Primed with Sphingosine-1 Phosphate on Pulmonary Artery Hypertension. Stem cells and development . 2015.

Ref Type: Generic


Figure 1: GPCR Signal Transduction. Each GPCR forms a complex with a unique Gα subunit. When the receptors are inactive the Gα subunit is inactive, bound to GDP and in a heterotrimeric conformation with βγ- subunits. The α and γ subunits are attached to the plasma membrane by lipid anchors. Once bound to a ligand, the receptor is activated and undergoes a conformational change, and the Gα subunit releases GDP, binds to GTP and is activated. The Gα subunit then releases the βγ complex leading to the activation of a variety of downstream effector molecules by the Gα subunit and βγ complex separately. The activated Gα subunit can bind to and activate a number of enzymes including adenylyl cyclase (AC) which catalyses ATP into cAMP. Increases in the concentration of cAMP lead to the activation of the PKA enzyme which in turn activates the downstream signalling pathways resulting in a variety of cellular responses including glucose regulation and inotropy. The cycle is completed when Gα-GTPase hydrolyzes GTP to GDP and becomes inactive. The G protein complex then re-couples the Gα with the Gβγ subunit.

Figure 2: Wnt Signalling Pathways. When Frizzled receptor (FZD) is bound to its agonist Wnt it can activate one of the three pathways: (a) the canonical pathway in which the activation of dishevelled (DVL) leads to the disassembly of the destruction complex; axin, adenomatosis polyposis coli (APC), glycogen synthase kinase 3β (GSK3β) from β-catenin. This in turn increases the cytosolic level of β-catenin which is then translocated to the nucleus and binds to transcription factor T-cell factor/lymphoid enhancer factor (TCF/LEF) activating the transcription of target genes. β-catenin is phosphorylated by GSK3β and degraded when there is no Wnt activation of FZD. Non canonical pathways include (b) Wnt-Calcium pathway in which DVL activates protein kinase C (PKC) leading to the release of intracellular calcium thereby activating a calcium/calmodulin-dependent protein kinase II (CaMKII) and (c) Wnt-planar cell polarity pathway in which the activation of DVL signals to Rho GTPases (Rho or Rac or both). While Ras activation is signalled through the c-Jun amino (N)-terminal kinase (JNK), the activation of Rho-GTPases induces changes in the cytoskeleton. To date it has been found that Wnt signalling can not only lead to a direct activation of DVL independent of the heterotrimeric G proteins as seen in (a) but may also lead to a G protein-DVL dependent activation whereby DVL can bind to or become activated subsequently by the G proteins in the cell.
Table 1. GPCRs with roles in hESC/hiPSC and differentiation to cardiovascular derivatives

<table>
<thead>
<tr>
<th>Maintenance and Survival</th>
<th>GPCR</th>
<th>Specie s</th>
<th>Cell Type</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1P</td>
<td>Human</td>
<td>ESC</td>
<td></td>
<td>(Pebay et al., 2005; Inniss et al., 2006; Wong et al., 2007)</td>
</tr>
<tr>
<td>LPA</td>
<td>Human</td>
<td>ESC</td>
<td></td>
<td>(Dottori et al., 2008)</td>
</tr>
<tr>
<td>CB1 &amp; CB2</td>
<td>Murine</td>
<td>ESC</td>
<td></td>
<td>(Jiang et al., 2007)</td>
</tr>
<tr>
<td>CXCR4</td>
<td></td>
<td>ESC</td>
<td></td>
<td>(Guo et al., 2005)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Self renewal/ pluripotency</th>
<th>GPCR</th>
<th>Specie s</th>
<th>Cell Type</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>FZD</td>
<td>Human</td>
<td>ESC</td>
<td></td>
<td>(Sato et al., 2004; Cai et al., 2007; Melchior et al., 2008b)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Migration</th>
<th>GPCR</th>
<th>Specie s</th>
<th>Cell Type</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CXCR4</td>
<td>Murine</td>
<td>ESC</td>
<td></td>
<td>(Guo et al., 2005)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reprogramming to iPSC</th>
<th>GPCR</th>
<th>Specie s</th>
<th>Cell Type</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>FZD</td>
<td>Murine</td>
<td>iPSC</td>
<td>iPSC</td>
<td>(Li et al., 2011; Marson et al., 2008)</td>
</tr>
<tr>
<td></td>
<td>Human</td>
<td>iPSC</td>
<td>iPSC</td>
<td>(Li et al., 2009)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiac Differentiation</th>
<th>GPCR</th>
<th>Specie s</th>
<th>Cell Type</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>FZD</td>
<td>Human</td>
<td>ESC/iPSC</td>
<td>ESC</td>
<td>(Minami et al., 2012; Lian et al., 2012)</td>
</tr>
<tr>
<td>APJ</td>
<td>Human</td>
<td>ESC</td>
<td>ESC</td>
<td>(Wang et al., 2012)</td>
</tr>
<tr>
<td>AT</td>
<td>Murine</td>
<td>ESC</td>
<td>ESC</td>
<td>(Wu et al., 2013)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Endothelial Differentiation</th>
<th>GPCR</th>
<th>Specie s</th>
<th>Cell Type</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>FZD</td>
<td>Human</td>
<td>iPSC</td>
<td></td>
<td>(Lian et al., 2014; Lippmann et al., 2012)</td>
</tr>
<tr>
<td>GPCR</td>
<td>Ligand</td>
<td>Role</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Platelet activating factor receptor (PAF)</td>
<td>Platelet activating factor (PAF)</td>
<td>Vascular permeability, increasing gap formation between endothelial cells</td>
<td>(Handley et al., 1984)</td>
<td></td>
</tr>
<tr>
<td>Histamine receptor (H)</td>
<td>Histamine</td>
<td>Vascular permeability</td>
<td>(Bakker et al., 2002)</td>
<td></td>
</tr>
<tr>
<td>Protease activated receptor (PAR)</td>
<td>Thrombin</td>
<td>Vascular permeability, cellular differentiation, migration and proliferation of VSMC, angiogenesis and vascular development</td>
<td>(Patterson et al., 2001)</td>
<td></td>
</tr>
<tr>
<td>S1PR</td>
<td>S1P</td>
<td>Stabilization of the endothelial barrier</td>
<td>(English et al., 1999)</td>
<td></td>
</tr>
<tr>
<td>CXCR4</td>
<td>SDF</td>
<td>Chemotaxis</td>
<td>(Hoggatt et al., 2013)</td>
<td></td>
</tr>
<tr>
<td>AT</td>
<td>Ang</td>
<td>Vasodilation, growth inhibition, vascular tone</td>
<td>(Pueyo et al., 1997)</td>
<td></td>
</tr>
<tr>
<td>ET</td>
<td>ET-1</td>
<td>Vasoconstriction, vascular homeostasis</td>
<td>(Kedzierski et al., 2001)</td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>Cell Source</td>
<td>Mutation</td>
<td>GPCRs Investigated</td>
<td>Phenotype</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-------------</td>
<td>---------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>LEOPARD syndrome</td>
<td>hiPSC</td>
<td>protein tyrosine phosphatase, non-receptor type 11 gene (PTPN11)</td>
<td>unknown</td>
<td>entigines, electrocardiographic abnormalities, ocular hypertelorism, pulmonary valve stenosis, abnormal genitalia, retardation of growth and deafness</td>
</tr>
<tr>
<td>Long QT syndromes (LQTS)</td>
<td>hiPSC</td>
<td>A614V missense mutation in the KCNH2 gene, c.A2987T (N996I) KCNH2 mutation, KCNH2 G1681A mutation</td>
<td>β-AR</td>
<td>delayed repolarization of the heart, arrhythmia</td>
</tr>
<tr>
<td>Catecholaminergic polymorphic ventricular tachycardia (CPVT)</td>
<td>hiPSC</td>
<td>p.F2483I mutation in ryanodine receptor 2</td>
<td>β-AR</td>
<td>Ventricular arrhythmia</td>
</tr>
<tr>
<td>Dilated cardiomyopathy (DCM)</td>
<td>hiPSC</td>
<td>Point mutation R173W in exon 12 of troponin T2 gene</td>
<td>β-AR</td>
<td>non-ischaemic cardiomyopathy</td>
</tr>
<tr>
<td>Hypertrophic cardiomyopathy (HCM)</td>
<td>hiPSC</td>
<td>missense mutation on exon 18 of the β-myosin heavy chain gene (Arg663His)</td>
<td>β-AR</td>
<td>non-ischaemic cardiomyopathy, enlargement of the cardiac cells</td>
</tr>
<tr>
<td>Arrhythmogenic right ventricular cardiomyopathy (ARVD)</td>
<td>hiPSC</td>
<td>c.2484C&gt;T mutation in PKP2</td>
<td>β-AR</td>
<td>Ventricular arrhythmia</td>
</tr>
<tr>
<td>Timothy syndrome</td>
<td>hiPSC</td>
<td>missense mutation in the L-type calcium channel CaV1.2</td>
<td>unknown</td>
<td>heart QT prolongation, arrhythmias, structural cardiac defects, webbing of fingers and toes and autism spectrum disorders</td>
</tr>
<tr>
<td>Barth syndrome</td>
<td>hiPSC</td>
<td>mutation of gene encoding tafazzin</td>
<td>unknown</td>
<td>Cardiomyopathy, neutropenia, underdeveloped skeletal musculature and muscle weakness, growth delay, cardiolipin abnormalities</td>
</tr>
<tr>
<td>Diabetic cardiomyopathy</td>
<td>hiPSC</td>
<td>N/A</td>
<td>Endothelin, β-AR</td>
<td>cardiomyopathy</td>
</tr>
<tr>
<td>Duchenne muscular dystrophy (DMD)</td>
<td>hiPSC</td>
<td>mutation in DMD gene encoding dystrophin</td>
<td>unknown</td>
<td>muscle degeneration and premature death</td>
</tr>
<tr>
<td>Down’s Syndrome</td>
<td>hESC</td>
<td>Trisomy 21</td>
<td>β-AR</td>
<td>delayed physical growth, facial features, and intellectual disability</td>
</tr>
</tbody>
</table>
(a) Wnt-canonical pathway

(b) Wnt-Calcium pathway

(c) Wnt-Planar cell polarity pathway